May 6 |
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
|
May 1 |
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
|
Apr 26 |
Belite Bio prices $25M direct offering
|
Apr 25 |
Belite Bio Announces $25 Million Registered Direct Offering
|
Apr 10 |
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?
|
Mar 22 |
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
|
Mar 20 |
Here's Why We're Not Too Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn Situation
|
Mar 12 |
Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
|
Mar 12 |
Belite Bio GAAP EPS of -$0.25 beats by $0.05
|
Mar 12 |
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
|